4891 Stock Overview
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TMS Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥246.00 |
| 52 Week High | JP¥460.00 |
| 52 Week Low | JP¥159.00 |
| Beta | 0 |
| 1 Month Change | -12.46% |
| 3 Month Change | -16.89% |
| 1 Year Change | -12.77% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4891 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 4.2% | 2.4% | 0.8% |
| 1Y | -12.8% | -24.1% | 26.5% |
Return vs Industry: 4891 exceeded the JP Biotechs industry which returned -24.1% over the past year.
Return vs Market: 4891 underperformed the JP Market which returned 26.5% over the past year.
Price Volatility
| 4891 volatility | |
|---|---|
| 4891 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4891's share price has been volatile over the past 3 months.
Volatility Over Time: 4891's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 14 | Takuro Wakabayashi | www.tms-japan.co.jp |
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development.
TMS Co., Ltd. Fundamentals Summary
| 4891 fundamental statistics | |
|---|---|
| Market cap | JP¥9.51b |
| Earnings (TTM) | -JP¥960.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.3x
P/E RatioIs 4891 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4891 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥960.04m |
| Earnings | -JP¥960.04m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4891 perform over the long term?
See historical performance and comparison